Biotech RadarJobs updated

COMPANY

RenovoRx

HQ: Mountain View, CA source · renovorx.com ↗

FDA-cleared device company Clinical Phase 3

Keywords: oncology Locally Advanced Pancreatic Cancer Pancreatic Neoplasms Pancreatic Cancer RenovoCath™ R120 Catheter Gemcitabine, local delivery

Location: Mountain View, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$10.0MRaised (2 yrs)4Trials (company is sponsor)

Timeline

  1. Raise Private placement: $10M (total, as published), announced Mar 23, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Apr 9, 2026 SEC Form D ↗
  2. Trial start —: PumaRx Registry Trial source ↗
  3. Trial start Phase 3: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC source ↗
  4. Trial start —: Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter source ↗
  5. Trial start Phase 1: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $10.0M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT03257033Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCPhase 3Active, not recruitingMar 12, 20182027-06 (estimated)
NCT06805461PumaRx Registry TrialNot listedRecruitingAug 1, 2025Sep 3, 2029 (estimated)
NCT02591082Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 CatheterNot listedCompleted2015-12Feb 26, 2021 (actual)
NCT02237157A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic CancerPhase 1Completed2015-032016-09 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback